Evidence map›Paper›PMID 41416726›Full record

ArticleACS infectious diseases2026

Tre-DST: A Drug Susceptibility Test for

Lilith A Schwartz, Adriann L Brodeth, Cara T Susilo, Amelia A Rodolf, Tanya Ivanov, Esmeralda Mendoza Corrales, Shivani S Kumar, Mireille Kamariza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Lilith A SchwartzUCLA Department of Chemistry and Biochemistry, Los Angeles, California 90095, United States.ORCID 0009-0002-3439-790X
Adriann L BrodethUCLA Department of Bioengineering, Los Angeles, California 90095, United States.
Cara T SusiloUCLA Department of Bioengineering, Los Angeles, California 90095, United States.
Amelia A RodolfUCLA Department of Bioengineering, Los Angeles, California 90095, United States.
Tanya IvanovUCLA Molecular Biology Institute, Los Angeles, California 90095, United States.
Esmeralda Mendoza CorralesUCLA Molecular Biology Institute, Los Angeles, California 90095, United States.
Shivani S KumarUCLA Department of Bioengineering, Los Angeles, California 90095, United States.
Mireille KamarizaUCLA Department of Bioengineering, Los Angeles, California 90095, United States.ORCID 0000-0003-1255-0803

Funding

Chemistry Biology Interface Training ProgramT32GM136614 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Patrick G. Harran · 2020 to 2026
$2.8M
A Rapid Phenotypic Drug Susceptibility Testing System for TuberculosisR01AI179891 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Mireille Kamariza · 2024 to 2026
$1.9M
Multiphoton Microscope for Deep Tissue ImagingS10OD025017 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENTOLILA, LAURENT A. · 2018 to 2018
$599k
NIAID NIH HHS R01 AI179891NIGMS NIH HHS T32 GM136614NIH HHS S10 OD025017
6 · The paper itself

Abstract

In 2024, an estimated 10 million people developed Tuberculosis (TB), nearly half a million of whom were infected with drug-resistant tuberculosis (DR-TB). Early detection of infection and drug resistance enables rapid engagement in effective care. Bacterial culture and nucleic acid testing remain the primary diagnostic methods, with smear microscopy being phased out. However, these methods present significant limitations for diagnosing drug resistance, such as lengthy time-to-result for phenotypic tests, as well as the need for prior knowledge of resistance mutations and prohibitive cost for molecular tests. To address this, we developed a rapid phenotypic TB drug susceptibility test, termed Tre-DST, based on novel metabolically incorporated trehalose probes, which specifically detect live mycobacteria. We used the nonpathogenic

Indexed as

Antitubercular AgentsMycobacterium tuberculosisTrehaloseDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMycobacterium smegmatisTuberculosis, Multidrug-ResistantAntitubercular AgentsTrehalosediagnosticsdrug resistancedrug susceptibilitymycobacteriaplate readersolvatochromic probestrehalosetuberculosis

Identifiers

PMID41416726
PMCPMC12797219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.